CY1105146T1 - Η χρηση οιστρογονικων αγωνιστων / ανταγωνιστων στην αγωγη της σεξουαλικης δυσλειτουργιας - Google Patents
Η χρηση οιστρογονικων αγωνιστων / ανταγωνιστων στην αγωγη της σεξουαλικης δυσλειτουργιαςInfo
- Publication number
- CY1105146T1 CY1105146T1 CY20061101124T CY061101124T CY1105146T1 CY 1105146 T1 CY1105146 T1 CY 1105146T1 CY 20061101124 T CY20061101124 T CY 20061101124T CY 061101124 T CY061101124 T CY 061101124T CY 1105146 T1 CY1105146 T1 CY 1105146T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- testosterone
- compositions
- female
- effective
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 229940011871 estrogen Drugs 0.000 title abstract 3
- 239000000262 estrogen Substances 0.000 title abstract 3
- 201000001880 Sexual dysfunction Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 231100000872 sexual dysfunction Toxicity 0.000 title 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 8
- 239000000203 mixture Substances 0.000 abstract 4
- 229960003604 testosterone Drugs 0.000 abstract 4
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 2
- 206010046542 Urinary hesitation Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 206010002261 Androgen deficiency Diseases 0.000 abstract 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Abstract
Αυτή η εφεύρεση είναι σχετική με τη χρήση αγωνιστών / ανταγωνιστών οιστρογόνων, για την παραγωγή φαρμάκων για την αγωγή καταστάσεων που ανταποκρίνονται στην αύξηση των επιπέδων τεστοστερόνης στο σώμα. Οι συνθέσεις αποτελούνται από έναν αγωνιστή / ανταγωνιστή οιστρογόνου και ένα φαρμακευτικά αποδεκτό έκδοχο, φορέα ή μέσο αραιώσεως. Αυτές οι συνθέσεις είναι αποτελεσματικές στην αγωγή της ανδρικής σεξουαλικής δυσλειτουργίας και της γυναικείας διστακτικότητας, όπου περιλαμβάνεται η χρονική περίοδος μετά την εμμηνόπαυση. Στην περίπτωση της ανδρικής στυτικής δυσλειτουργίας, οι συνθέσεις μπορούν ακόμη να περιλαμβάνουν μία ένωση η οποία αυξάνει την 5-μονοφωσφορική κυκλική γουανοσίνη 3', (cGMP). Ακόμη, οι συνθέσεις είναι αποτελεσματικές και σε άλλες καταστάσεις των οποίων η αιτιολογία είναι αποτέλεσμα ανεπάρκειας τεστοστερόνης, ή που μπορούν να βελτιωθούν με την αύξηση των επιπέδων τεστοστερόνης στο. σώμα. Οι χρήσεις, σύμφωνα με την εφεύρεση, περιλαμβάνουν την αγωγή των καταστάσεων που ανταποκρίνονται στην αύξηση των επιπέδων τεστοστερόνης, όπως είναι η αγωγή της ανδρικής σεξουαλικής δυσλειτουργίας και η γυναικεία διστακτικότητα, περιλαμβανομένης της χρονικής περιόδου μετά την εμμηνόπαυση και της αυξήσεως της σεξουαλικής ορμής (Libido) του θηλυκού. Οι χρήσεις σύμφωνα με την εφεύρεση είναι αποτελεσματικές, ενώ ταυτόχρονα μειώνουν τον κίνδυνο παρενεργειών που συνοδεύει την χορήγηση τεστοστερόνης.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17570400P | 2000-01-12 | 2000-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105146T1 true CY1105146T1 (el) | 2010-03-03 |
Family
ID=22641295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101124T CY1105146T1 (el) | 2000-01-12 | 2006-08-10 | Η χρηση οιστρογονικων αγωνιστων / ανταγωνιστων στην αγωγη της σεξουαλικης δυσλειτουργιας |
Country Status (19)
Country | Link |
---|---|
US (2) | US6512002B2 (el) |
EP (1) | EP1125582B1 (el) |
JP (1) | JP2001233791A (el) |
KR (1) | KR100485856B1 (el) |
AT (1) | ATE334674T1 (el) |
AU (1) | AU784439B2 (el) |
CA (1) | CA2331009C (el) |
CO (1) | CO5271697A1 (el) |
CY (1) | CY1105146T1 (el) |
DE (1) | DE60121841T2 (el) |
DK (1) | DK1125582T3 (el) |
ES (1) | ES2266110T3 (el) |
HU (1) | HUP0100121A3 (el) |
IL (1) | IL140803A0 (el) |
MY (1) | MY133954A (el) |
NZ (1) | NZ509320A (el) |
PE (1) | PE20011119A1 (el) |
PT (1) | PT1125582E (el) |
ZA (1) | ZA200100176B (el) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4894697A (en) * | 1997-10-01 | 1999-04-23 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20030077228A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20050287075A1 (en) * | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20090162300A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing alprazolam |
US20040136914A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
EP1222190A1 (en) * | 1999-10-11 | 2002-07-17 | Pfizer Limited | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
US6245819B1 (en) | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
GB0105893D0 (en) * | 2001-03-09 | 2001-04-25 | Pfizer Ltd | Pharmaceutically active compounds |
HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
EP1442042A1 (en) * | 2001-11-09 | 2004-08-04 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
JP4667369B2 (ja) | 2003-03-21 | 2011-04-13 | ネックスメド ホールディングス インコーポレイテッド | 早漏を治療するための組成物および方法 |
DE102004030099A1 (de) * | 2004-06-22 | 2006-01-12 | Grünenthal GmbH | Gesättigte und ungesättigte 3-Pyridyl-benzocycloalkylmethyl-amine als Serotonin- und/oder Noradrenalin-Reuptake-Hemmer und/oder µ-Opioidrezeptor-Modulatoren |
US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
MX2007000762A (es) | 2004-07-22 | 2007-04-02 | Ptc Therapeutics Inc | Tienopiridinas para tratamientode hepatitis c. |
US20060293294A1 (en) * | 2004-09-03 | 2006-12-28 | Hormos Medical Corporation | Method for treatment or prevention of androgen deficiency |
CA2578852A1 (en) * | 2004-09-03 | 2006-03-09 | Hormos Medical Corporation | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
TW200637553A (en) * | 2004-12-14 | 2006-11-01 | Shionogi & Co | Indlomorphinane derivatives having a carboxy group at 6' position |
JP2009502302A (ja) | 2005-07-25 | 2009-01-29 | グロス,ヨシ | 血管の電気刺激 |
US20070248548A1 (en) * | 2006-04-19 | 2007-10-25 | Blondino Frank E | Stable hydroalcoholic oral spray formulations and methods |
EP2124897A4 (en) * | 2006-12-22 | 2012-05-09 | Novadel Pharma Inc | SPRAYING, ORAL, STABLE, SPRAY PREPARATIONS AND ASSOCIATED METHODS |
WO2008099060A2 (en) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
CN101636372B (zh) | 2007-02-14 | 2013-03-27 | 霍尔莫斯医疗有限公司 | 有治疗价值的三苯基丁烯衍生物的制备方法 |
US8152711B2 (en) * | 2007-03-21 | 2012-04-10 | Yossi Gross | Implantable peristaltic pump to treat erectile dysfunction |
AU2008251370A1 (en) * | 2007-05-10 | 2008-11-20 | Novadel Pharma Inc. | Anti-insomnia compositions and methods |
US20080312239A1 (en) * | 2007-06-13 | 2008-12-18 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
US7985325B2 (en) * | 2007-10-30 | 2011-07-26 | Novellus Systems, Inc. | Closed contact electroplating cup assembly |
US8538535B2 (en) | 2010-08-05 | 2013-09-17 | Rainbow Medical Ltd. | Enhancing perfusion by contraction |
US8626290B2 (en) | 2008-01-31 | 2014-01-07 | Enopace Biomedical Ltd. | Acute myocardial infarction treatment by electrical stimulation of the thoracic aorta |
US8626299B2 (en) | 2008-01-31 | 2014-01-07 | Enopace Biomedical Ltd. | Thoracic aorta and vagus nerve stimulation |
US9005106B2 (en) | 2008-01-31 | 2015-04-14 | Enopace Biomedical Ltd | Intra-aortic electrical counterpulsation |
US7818062B2 (en) * | 2008-01-31 | 2010-10-19 | Ed Tech Medical Ltd. | Peristaltic pump for treatment of erectile dysfunction |
CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | 雌激素受体调节剂及其用途 |
US8649863B2 (en) | 2010-12-20 | 2014-02-11 | Rainbow Medical Ltd. | Pacemaker with no production |
US9526637B2 (en) | 2011-09-09 | 2016-12-27 | Enopace Biomedical Ltd. | Wireless endovascular stent-based electrodes |
US8855783B2 (en) | 2011-09-09 | 2014-10-07 | Enopace Biomedical Ltd. | Detector-based arterial stimulation |
US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
US9386991B2 (en) | 2012-02-02 | 2016-07-12 | Rainbow Medical Ltd. | Pressure-enhanced blood flow treatment |
EP2822556A1 (en) | 2012-03-07 | 2015-01-14 | Ligand Pharmaceuticals Inc. | Steroid hormone and cholesterol pathways as one unified homestatic system |
WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
US10779965B2 (en) | 2013-11-06 | 2020-09-22 | Enopace Biomedical Ltd. | Posts with compliant junctions |
US9855281B2 (en) * | 2013-11-20 | 2018-01-02 | Scott Freeman Consultant, Llc | Libido-enhancing therapeutic and use |
KR20180071274A (ko) | 2015-10-01 | 2018-06-27 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
MX2018007079A (es) | 2015-12-09 | 2018-11-12 | The Board Of Trustees Of Univ Of Illinois | Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno. |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
JP2019520379A (ja) | 2016-07-01 | 2019-07-18 | ジー1 セラピューティクス, インコーポレイテッド | ピリミジン系の抗増殖剤 |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
KR102507967B1 (ko) | 2016-09-09 | 2023-03-09 | 인사이트 코포레이션 | Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암을 치료하기 위한 이의 용도 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
PL3525774T3 (pl) | 2016-10-11 | 2022-04-25 | Duke University | Leczenie lazofoksyfenem raka piersi er+ |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
RU2019142591A (ru) | 2017-06-29 | 2021-07-29 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
WO2019199891A1 (en) | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物 |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
CN114450276A (zh) | 2019-08-06 | 2022-05-06 | 因赛特公司 | Hpk1抑制剂的固体形式 |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
IL120262A (en) * | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
TW442286B (en) | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
JP3008891B2 (ja) | 1997-05-08 | 2000-02-14 | 日本電気株式会社 | 成形ビームアレイアンテナ |
-
2000
- 2000-12-27 CO CO00097876A patent/CO5271697A1/es not_active Application Discontinuation
-
2001
- 2001-01-05 PT PT01300061T patent/PT1125582E/pt unknown
- 2001-01-05 EP EP01300061A patent/EP1125582B1/en not_active Expired - Lifetime
- 2001-01-05 DK DK01300061T patent/DK1125582T3/da active
- 2001-01-05 ES ES01300061T patent/ES2266110T3/es not_active Expired - Lifetime
- 2001-01-05 AT AT01300061T patent/ATE334674T1/de not_active IP Right Cessation
- 2001-01-05 DE DE60121841T patent/DE60121841T2/de not_active Expired - Lifetime
- 2001-01-08 ZA ZA200100176A patent/ZA200100176B/xx unknown
- 2001-01-08 IL IL14080301A patent/IL140803A0/xx not_active IP Right Cessation
- 2001-01-09 PE PE2001000017A patent/PE20011119A1/es not_active Application Discontinuation
- 2001-01-10 AU AU11129/01A patent/AU784439B2/en not_active Ceased
- 2001-01-10 US US09/757,423 patent/US6512002B2/en not_active Expired - Lifetime
- 2001-01-10 JP JP2001002462A patent/JP2001233791A/ja active Pending
- 2001-01-10 MY MYPI20010098A patent/MY133954A/en unknown
- 2001-01-10 CA CA002331009A patent/CA2331009C/en not_active Expired - Fee Related
- 2001-01-11 NZ NZ509320A patent/NZ509320A/en unknown
- 2001-01-11 HU HU0100121A patent/HUP0100121A3/hu unknown
- 2001-01-11 KR KR10-2001-0001511A patent/KR100485856B1/ko not_active IP Right Cessation
-
2002
- 2002-11-21 US US10/301,930 patent/US20030114440A1/en not_active Abandoned
-
2006
- 2006-08-10 CY CY20061101124T patent/CY1105146T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2001233791A (ja) | 2001-08-28 |
AU1112901A (en) | 2001-07-19 |
DK1125582T3 (da) | 2006-10-30 |
EP1125582B1 (en) | 2006-08-02 |
CA2331009A1 (en) | 2001-07-12 |
NZ509320A (en) | 2002-06-28 |
EP1125582A3 (en) | 2002-04-17 |
ATE334674T1 (de) | 2006-08-15 |
DE60121841T2 (de) | 2007-07-26 |
CO5271697A1 (es) | 2003-04-30 |
KR100485856B1 (ko) | 2005-04-28 |
CA2331009C (en) | 2005-10-25 |
HU0100121D0 (en) | 2001-03-28 |
US20010044434A1 (en) | 2001-11-22 |
US6512002B2 (en) | 2003-01-28 |
HUP0100121A2 (en) | 2002-10-28 |
IL140803A0 (en) | 2002-02-10 |
EP1125582A2 (en) | 2001-08-22 |
US20030114440A1 (en) | 2003-06-19 |
ES2266110T3 (es) | 2007-03-01 |
AU784439B2 (en) | 2006-04-06 |
HUP0100121A3 (en) | 2004-04-28 |
MY133954A (en) | 2007-11-30 |
ZA200100176B (en) | 2002-07-08 |
PE20011119A1 (es) | 2001-11-05 |
KR20010070500A (ko) | 2001-07-25 |
PT1125582E (pt) | 2006-11-30 |
DE60121841D1 (de) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105146T1 (el) | Η χρηση οιστρογονικων αγωνιστων / ανταγωνιστων στην αγωγη της σεξουαλικης δυσλειτουργιας | |
EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
ZA200104396B (en) | Compositions and methods for stimulating gastrointestinal motility. | |
DE602004020638D1 (de) | Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten | |
ZA200103148B (en) | Compositions and methods for treating female sexual dysfunction. | |
ES2174129T3 (es) | Antagonistas de la hormona de liberacion de la gonadotropina. | |
NO20015599D0 (no) | Hjelpemidler eller preventive midler for sykdom assosiert med kjemokiner | |
EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
NZ504487A (en) | Combination of alpha-adrenergic antagonists and cGMP elevators for the treatment of impotence | |
AR029373A1 (es) | Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas | |
HRP20050872A2 (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
NO20040500L (no) | 1, 3, 5-triazin-2, 4, 6-trioner, fremstilling og anvendelse som gonadotropin-frigjorende hormon reseptor antagonister | |
ATE384066T1 (de) | Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren | |
CO5410176A1 (es) | Composiciones mejoradas para el tratamiento de la disfuncion erectil masculina | |
TH54250A3 (th) | สารผสมตามสูตรที่ใช้เข้าทางจมูกสำหรับรักษาความผิดปกติทางเพศ | |
DE60314158D1 (de) | Pyrazolderivate als gnrh-inhibitoren | |
ECSP993058A (es) | Antagonistas de la hormona liberadora de gonadotropina |